{"id":"bmn-110-every-other-week","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4754894","moleculeType":"Unknown","molecularWeight":"377.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMN 110 is designed to replace the deficient lysosomal acid lipase enzyme, which normally breaks down cholesterol esters and triglycerides within lysosomes. In LAL deficiency (also known as Wolman disease or cholesteryl ester storage disease), accumulation of these lipids causes multi-organ damage. The every-other-week dosing regimen aims to maintain therapeutic enzyme levels with reduced infusion frequency compared to weekly alternatives.","oneSentence":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:30.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)"}]},"trialDetails":[{"nctId":"NCT01415427","phase":"PHASE3","title":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2011-07","conditions":"Mucopolysaccharidosis IV A, Morquio A Syndrome, MPS IVA","enrollment":173},{"nctId":"NCT01275066","phase":"PHASE3","title":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2011-02","conditions":"MPS IV A","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["N-acetylgalactosamine-6-sulfatase","N-acetylgalactosamine-6-sulfate sulfatase","galactose-6-sulfatase","GALNS","enzyme replacement therapy"],"phase":"phase_3","status":"active","brandName":"BMN 110 - Every Other Week","genericName":"BMN 110 - Every Other Week","companyName":"BioMarin Pharmaceutical","companyId":"biomarin-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency. Used for Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}